טוען...
HDAC inhibition overcomes acute resistance to MEK inhibition in BRAF mutant colorectal cancer by down-regulation of c-FLIP(L)
PURPOSE: Activating mutations in the BRAF oncogene are found in 8-15% of colorectal cancer (CRC) patients and have been associated with poor survival. In contrast to BRAF mutant (MT) melanoma, inhibition of the MAPK pathway is ineffective in the majority of BRAFMT CRC patients. Therefore, identifica...
שמור ב:
| הוצא לאור ב: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4504978/ https://ncbi.nlm.nih.gov/pubmed/25813020 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2701 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|